Skip to main content

Table 4 Clinical characteristics in the GETE score using a univariate and multivariate logistic regression

From: Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

  GETE ≥ good (n = 14) GETE ≤ moderate (n = 10) odds ratio (95%CI) (univariate) p value odds ratio (95%CI) (multivariate) p value
sex (male), n (%) 4 (29) 5 (50) 0.40 (0.07–2.2) 0.29
age (≥ 65 year-old), n (%) 5 (36) 4 (40) 0.83 (0.16–4.4) 0.83
BMI (≥ 25) (kg/m2), n (%) 3 (21) 5 (50) 0.27 (0.05–1.6) 0.15 0.1 (0.004–2.8) 0.18
bEOS (≥ 300) (/μl), n (%) 7 (50) 3 (30) 2.3 (0.42–12.9) 0.33 11.2 (0.57–219) 0.11
bBASO (≥ 40) (/μl), n (%) 4 (29) 3 (30) 0.93 (0.16–5.5) 0.94
FeNO (≥ 50) (ppb), n (%) 9 (64) 3 (30) 3.6 (0.62–21) 0.15 3.7 (0.24–57) 0.35
MEPO (+), n (%) 6 (43) 5 (50) 0.75 (0.15–3.8) 0.73
comorbidities
 —with AERD, n (%) 2 (14) 5 (50) 0.17 (0.02–1.2) 0.07 0.035 (0.002–0.72) 0.03
 —with ECRS, n (%) 12 (86) 8 (80) 1.5 (0.17–13) 0.71 0.51 (0.006–41) 0.76
  1. Abbreviations: GETE Global Evaluation of Treatment Effectiveness, BMI body mass index, bEOS peripheral blood eosinophil count at baseline, bBASO peripheral basophil count at baseline, FeNO fractional exhaled nitric oxide, ppb parts-per-billion, MEPO previous mepolizumab treatment, AERD aspirin-exacerbated respiratory disease, ECRS eosinophilic chronic rhinosinusitis